公开(公告)号：US12083224B2

公开(公告)日：2024-09-10

申请号：US17042848

申请日：2019-04-01

Applicant: Arcturus Therapeutics, Inc.

Inventor： Padmanabh Chivukula ,  Priya Karmali ,  Christine Esau ,  Jerel Vega ,  Yanjie Bao ,  Rajesh Mukthavaram ,  Samantha Murphy

IPC: A61K31/7088 ,  A61K9/127 ,  A61K31/7105 ,  A61K31/711 ,  A61K39/12

CPC classification number: A61K9/1272 ,  A61K31/7105 ,  A61K31/711 ,  A61K39/12

Abstract: Nucleic acid immunization is achieved by delivering a nucleic acid (NA), e.g., a mRNA or a DNA, encapsulated within a lipid-NA nanoparticle. The NA encodes an immunogenic compound of interest. The lipid-NA nanoparticle is effective for in vivo delivery of NA to a vertebrate cell, including upon administration to a subject. The lipid-NA nanoparticle are incorporated in pharmaceutical compositions for immunizing subjects against various diseases.

公开(公告)号：US20210292768A1

公开(公告)日：2021-09-23

申请号：US17266556

申请日：2019-08-08

Applicant: ARCTURUS THERAPEUTICS, INC.

Inventor： Kiyoshi Tachikawa ,  Padmanabh Chivukula ,  Lily Xu ,  Angel Leu ,  Marciano Sablad ,  Rajesh Mukthavaram ,  Priya Karmali

IPC: C12N15/113 ,  A61P1/16

Abstract: This disclosure encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting expression of PDGFRB in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers.

公开(公告)号：US20220378702A1

公开(公告)日：2022-12-01

申请号：US17737862

申请日：2022-05-05

Applicant: Arcturus Therapeutics, Inc.

Inventor： Kumar Rajappan ,  Steven Tanis ,  Rajesh Mukthavaram ,  Amit Sagi ,  Priya Prakash Karmali ,  Padmanabh Chivukula

IPC: A61K9/127 ,  C07K19/00 ,  A61K31/7105

Abstract: Peptides and Peptide-lipid conjugates are provided in which the peptide has the general Formula (I) wherein, A1 is selected from serine, threonine, O—C1-6 alkyl serine, and O—C1-6 alkyl threonine; A2 is selected from serine, threonine, O—C1-6 alkyl serine, and O—C1-6 alkyl threonine; A3 is selected from glutamic acid, glutamine, asparagine, and aspartic acid; A4 is proline; each A5 is independently selected from a natural or modified amino acid; The peptide-lipid conjugates can be used in lipid formulations for the delivery of nucleic acids.

公开(公告)号：US20220370624A1

公开(公告)日：2022-11-24

申请号：US17737884

申请日：2022-05-05

Applicant: Arcturus Therapeutics, Inc.

Inventor： Kumar Rajappan ,  Steven Tanis ,  Rajesh Mukthavaram ,  Amit Sagi ,  Priya Prakash Karmali ,  Padmanabh Chivukula

IPC: A61K47/54 ,  A61K47/26 ,  C07K7/04 ,  C07K14/00 ,  C07K19/00 ,  A61P35/00 ,  A61K9/00

Abstract: A lipid composition containing a nucleic acid, wherein the lipid composition comprises a peptide-lipid conjugate, is provided. The peptide of the peptide-lipid conjugates can be from 4 to 52 amino acids in length. Methods of using the lipid composition in the in vivo delivery of nucleic acids are further provided.

公开(公告)号：US12070509B2

公开(公告)日：2024-08-27

申请号：US17246558

申请日：2021-04-30

Applicant: Arcturus Therapeutics, Inc.

Inventor： Carlos G. Perez-Garcia ,  Kiyoshi Tachikawa ,  Daiki Matsuda ,  Padmanabh Chivukula ,  Priya Prakash Karmali ,  Yanjie Bao ,  Jerel Boyd Lee Vega ,  Rajesh Mukthavaram ,  Amit Sagi

IPC: A61K48/00 ,  A61P11/00 ,  C07K14/47

CPC classification number: A61K48/0033 ,  A61K48/005 ,  A61P11/00 ,  C07K14/4702

Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.

公开(公告)号：US20230219996A1

公开(公告)日：2023-07-13

申请号：US17816243

申请日：2022-07-29

Applicant: Arcturus Therapeutics, Inc.

Inventor： Daiki MATSUDA ,  Sean Michael Sullivan ,  Kiyoshi Tachikawa ,  Padmanabh Chivukula ,  Priya Prakash Karmali ,  Yanjie Bao ,  Amit Sagi ,  Rajesh Mukthavaram

IPC: C07H21/02 ,  C07K14/18 ,  C07K14/165 ,  C07K14/11 ,  A61K9/127 ,  A61K47/14 ,  A61K47/28 ,  A61K9/19

CPC classification number: C07H21/02 ,  A61K9/19 ,  A61K9/127 ,  A61K47/14 ,  A61K47/28 ,  C07K14/11 ,  C07K14/165 ,  C07K14/1808

Abstract: Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

公开(公告)号：US20220023442A1

公开(公告)日：2022-01-27

申请号：US17246558

申请日：2021-04-30

Applicant: Arcturus Therapeutics, Inc.

Inventor： Carlos G. Perez-Garcia ,  Kiyoshi Tachikawa ,  Daiki Matsuda ,  Padmanabh Chivukula ,  Priya Prakash Karmali ,  Yanjie Bao ,  Jerel Boyd Lee Vega ,  Rajesh Mukthavaram ,  Amit Sagi

IPC: A61K48/00 ,  C07K14/47 ,  A61P11/00

Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.